Tags

Type your tag names separated by a space and hit enter

Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial.
J Ayub Med Coll Abbottabad. 2007 Oct-Dec; 19(4):58-63.JA

Abstract

BACKGROUND

The tolerability and efficacy for patients with obsessive-compulsive disorder (OCD) in a large, sample on Escitalopram was studied.

METHODS

A total of 100 adults with a confirmed diagnosis of OCD were included. The percentage of patients with an adequate drug trial, defined as 42 days of continuous treatment with a serotonin- reuptake inhibitor or placebo at dosages at or above established minimal effective dosages.

RESULTS

Ninety-six percent of the adults who were newly diagnosed with OCD in the index year had an adequate trial of medication after their first visit for OCD. By the second half of 42 days the patient who were responding to the treatment were randomly allocated to two groups. One group received the same drug and other group was given placebo. The results were complied at the end of three months of each patient treatment. No additional psychotherapy was offered to these patients during this time period.

CONCLUSIONS

Despite the typically chronic course of OCD, many patients with OCD responded to the Esciatolpram at the dosage of twenty milligram per day.

Authors+Show Affiliations

Department of Psychiatry, SIMS & Services Hospital, Lahore. nasarsayeed@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18693600

Citation

Khan, M Nasar Sayeed, et al. "Escitalopram in the Treatment of Obsessive-compulsive Disorder: a Double Blind Placebo Control Trial." Journal of Ayub Medical College, Abbottabad : JAMC, vol. 19, no. 4, 2007, pp. 58-63.
Khan MN, Hotiana UA, Ahmad S. Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. J Ayub Med Coll Abbottabad. 2007;19(4):58-63.
Khan, M. N., Hotiana, U. A., & Ahmad, S. (2007). Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. Journal of Ayub Medical College, Abbottabad : JAMC, 19(4), 58-63.
Khan MN, Hotiana UA, Ahmad S. Escitalopram in the Treatment of Obsessive-compulsive Disorder: a Double Blind Placebo Control Trial. J Ayub Med Coll Abbottabad. 2007 Oct-Dec;19(4):58-63. PubMed PMID: 18693600.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. AU - Khan,M Nasar Sayeed, AU - Hotiana,Usman Amin, AU - Ahmad,Salman, PY - 2008/8/13/pubmed PY - 2008/10/10/medline PY - 2008/8/13/entrez SP - 58 EP - 63 JF - Journal of Ayub Medical College, Abbottabad : JAMC JO - J Ayub Med Coll Abbottabad VL - 19 IS - 4 N2 - BACKGROUND: The tolerability and efficacy for patients with obsessive-compulsive disorder (OCD) in a large, sample on Escitalopram was studied. METHODS: A total of 100 adults with a confirmed diagnosis of OCD were included. The percentage of patients with an adequate drug trial, defined as 42 days of continuous treatment with a serotonin- reuptake inhibitor or placebo at dosages at or above established minimal effective dosages. RESULTS: Ninety-six percent of the adults who were newly diagnosed with OCD in the index year had an adequate trial of medication after their first visit for OCD. By the second half of 42 days the patient who were responding to the treatment were randomly allocated to two groups. One group received the same drug and other group was given placebo. The results were complied at the end of three months of each patient treatment. No additional psychotherapy was offered to these patients during this time period. CONCLUSIONS: Despite the typically chronic course of OCD, many patients with OCD responded to the Esciatolpram at the dosage of twenty milligram per day. SN - 1025-9589 UR - https://www.unboundmedicine.com/medline/citation/18693600/Escitalopram_in_the_treatment_of_obsessive_compulsive_disorder:_a_double_blind_placebo_control_trial_ L2 - http://www.diseaseinfosearch.org/result/5285 DB - PRIME DP - Unbound Medicine ER -